Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant
11/12/2025 05:31
Dec 11 (Reuters) - Suven Life Sciences Ltd SUVP.NS: SUVEN LIFE SCIENCES - 100% PATIENT ENROLMENT MILESTONE IN PHASE-2B CLINICAL TRIAL OF ROPANICANT Source text: [ID:] Further company coverage: SUVP.NS (Reporting by Abhirami G from Bengaluru) ((abhirami.g@thomsonreuters.com;))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Patient Enrollment In Global Phase-3 Masupirdine Study
India's Suven Life Sciences gains after Masupirdine Phase-3 study completes patient enrollment
Brief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant